Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 144,580 shares of its common stock to eighteen new employees.
- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 144,580 shares of its common stock to eighteen new employees.
- These inducement stock options have a grant date of May 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
- The inducement stock options are subject to the terms and conditions of Biocepts Amended and Restated 2013 Equity Incentive Plan.
- Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.